Match!

Changes in clinical trial length

Published on May 1, 2015in Nature Reviews Drug Discovery57.618
· DOI :10.1038/nrd4611
Lisette Pregelj5
Estimated H-index: 5
,
Martie-Louise Verreynne14
Estimated H-index: 14
,
Damian Hine10
Estimated H-index: 10
Abstract
This analysis of changes in the length of clinical trials over time provides evidence of increased efficiency in drug development and investigates the possible contributing factors.
  • References (0)
  • Citations (5)
📖 Papers frequently viewed together
88 Citations
25 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References0
Newest
Cited By5
Newest
#1Ying Hong Li (ZJU: Zhejiang University)H-Index: 9
#2Xiao Xu Li (ZJU: Zhejiang University)H-Index: 6
Last. Feng Zhu (ZJU: Zhejiang University)H-Index: 30
view all 13 authors...
: Drugs produce their therapeutic effects by modulating specific targets, and there are 89 innovative targets of first-in-class drugs approved in 2004-17, each with information about drug clinical trial dated back to 1984. Analysis of the clinical trial timelines of these targets may reveal the trial-speed differentiating features for facilitating target assessment. Here we present a comprehensive analysis of all these 89 targets, following the earlier studies for prospective prediction of clini...
21 CitationsSource
#1Véronique Boyer (University of Montpellier)H-Index: 1
#2Antoine Vilotitch (AMU: Aix-Marseille University)H-Index: 5
Last. Marion MoraH-Index: 11
view all 13 authors...
Abstract Context Twenty years after the advent of combined antiretroviral therapies (ARTs), there is a growing need for up-to-date information about the daily experience of people living with HIV (PLWH). Objectives This study aimed to investigate the relationship between socioepidemiological groups and the types of bothersome symptoms reported by PLWH participating in a national survey in France. Methods We analyzed self-reported bothersome symptoms in a representative sample of PLWH (ANRS-VESPA...
1 CitationsSource
#1Christos Fountzilas (Hellenic Naval Academy)H-Index: 5
#2Selena Stuart (University of Texas Health Science Center at San Antonio)H-Index: 1
Last. Devalingam Mahalingam (University of Texas Health Science Center at San Antonio)H-Index: 27
view all 10 authors...
Introduction The goal of organ dysfunction Phase I trials is to characterize the safety and pharmacokinetics of novel agents in cancer patients with liver or kidney dysfunction, but the clinical benefit is not well established. Methods We reviewed 170 patients across 15 liver dysfunction studies at our institution, grouped based on the NCI-Organ Dysfunction Working Group criteria or Child-Pugh Score. Results The median survival for the entire cohort was two months and just one month amongst pati...
2 CitationsSource
#1Russ B. Altman (Stanford University)H-Index: 77
#2Natalia Khuri (Stanford University)H-Index: 8
Last. Kathleen M. Giacomini (UCSF: University of California, San Francisco)H-Index: 67
view all 4 authors...
A plethora of innovative new medical products along with the need to apply modern technologies to medical-product evaluation has spurred seminal opportunities in regulatory sciences. Here, we provide eight examples of regulatory science research for diverse products. Opportunities abound, particularly in data science and precision health.
6 CitationsSource
#1Derek J. Ward (University of Birmingham)H-Index: 8
#2Edward Hammond (University of Birmingham)H-Index: 1
Last. Andrew Stevens (University of Birmingham)H-Index: 30
view all 4 authors...
Objectives Recent decades have witnessed the development of highly innovative new antiviral drug therapies. However, there are concerns that rising costs and lengthening development times could have implications for future patient access to innovative new drugs. We sought to establish whether the time taken for the clinical development of new antiviral drugs launched in the UK had increased since the 1980s. Design and setting Retrospective observational study of all new antiviral drugs licensed ...
2 CitationsSource